Source comparison
Peptide Class Comparison: Dosing and Receptor Mechanisms
CJC-1295 (no DAC) GHRH receptor 100–200mcg ~30 minutes 2–3x daily Short half-life requires multiple daily doses but avoids DAC's prolonged receptor desensitization. Best for mimicking natural GH pulsatility CJC-1295 with DAC 2mg 6–8 days Once weekly Extended h
This comparison does not assign a generated winner or score.
- CJC-1295 (no DAC)
- GHRH receptor
- 100–200mcg
- ~30 minutes
- 2–3x daily
- Short half-life requires multiple daily doses but avoids DAC's prolonged receptor desensitization. Best for mimicking natural GH pulsatility
- CJC-1295 with DAC
- 2mg
- 6–8 days
- Once weekly
- Extended half-life from Drug Affinity Complex allows single weekly dosing but risks continuous receptor occupancy that may blunt endogenous pulses over time
- Ipamorelin
- Ghrelin receptor (GHSR-1a)
- 200–300mcg
- 2 hours
- Highly selective ghrelin mimetic with minimal cortisol/prolactin elevation. Preferred for long-term use due to favorable side effect profile
- GHRP-2
- 100–300mcg
- 90 minutes
- Stronger GH release than ipamorelin but increases cortisol and appetite via non-selective ghrelin pathway activation
- MK-677 (Ibutamoren)
- Ghrelin receptor (oral)
- 10–25mg
- 24 hours
- Once daily
- Orally bioavailable ghrelin mimetic. Convenient but causes prolonged hunger elevation and potential insulin resistance with chronic use
- Hexarelin
- 70 minutes
- 2x daily
- Potent GH releaser but rapid receptor desensitization limits efficacy beyond 2–4 weeks. Best used in short cycles